Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbhfiledCriticalImmatics Biotechnologies Gmbh
Priority to CL2022002191ApriorityCriticalpatent/CL2022002191A1/en
Publication of CL2022002191A1publicationCriticalpatent/CL2022002191A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Peptides Or Proteins
(AREA)
Abstract
La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos t asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos t que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (mhc), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos t solubles, y de otras moléculas de unión.The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to immunotherapy against cancer. The present invention also relates to peptide epitopes for tumor-associated T-lymphocytes, alone or in combination with other tumor-associated peptides which, for example, can serve as active pharmaceutical ingredients in vaccine compositions intended to stimulate antitumor immune responses, or to stimulate ex live T-lymphocytes that will then be transferred to patients. Peptides bound to major histocompatibility complex (mhc) molecules, or peptides as such, can also be targets of antibodies, soluble T cell receptors, and other binding molecules.
CL2022002191A2022-08-122022-08-12
Peptides and their combinations for use in immunotherapy against various types of cancer
CL2022002191A1
(en)
Novel peptides and novel peptide combinations as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma, as well as other types of cancer (divisional application no. 201803293)
PEPTIDES AND COMBINATION OF PEPTIDES AS A TARGET AND FOR USE IN IMMUNOTHERAPY AGAINST CANCER OF BILIARY VESICLE AND COLANGIOCARCINOMA, AS WELL AS OTHER TYPES OF CANCER